Seminars in Hematology
Volume 41, Issue 1 , Pages 4-14 , January 2004

Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura

  • Joel L Moake

      Affiliations

    • Baylor College of Medicine and Rice University, Houston, TX, USA
    • Corresponding Author InformationAddress correspondence to Joel L. Moake, MD, Medical Hematology Section, The Methodist Hospital, Mail Station 902, Main Bldg, 6565 Fannin St, Houston, TX 77030, USA

References 

  1. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries (A hitherto undescribed disease). Proc NY Pathol Soc. 1924;24:21–24
  2. Moschcowitz E. An acute febrile pleiochromic anamia with hyaline thrombosis of the terminal arterioles and capillaries. Arch Intern Med. 1925;36:89–93
  3. Marcus AJ. Dr. Eli Moschcowitz. In:  Kaplan BS,  Trompeter RS,  Moake JL editor. Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. New York, NY: Marcel Dekker; 1992;p. 19–27
  4. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589–600
  5. Cohen JA, Brecher ME, Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apheresis. 1998;13:16–19
  6. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura (Report of 16 cases and review of the literature). Medicine. 1966;45:139–159
  7. Moake JL, Byrnes JJ. Thrombotic microangiopathies associated with drugs and bone marrow transplantation. Hematol Oncol Clin North Am. 1996;10:485–497
  8. Singh N, Gayowski T, Marino IR. Hemolytic uremic syndrome in solid-organ transplant recipients. Transplant Int. 1996;9:68–75
  9. Gottschall JL, Elliot W, Lianos E, McFarland JG, Wolfmeyer K, Aster RH. Quinine-induced immune thrombocytopenia associated with hemolytic-uremic syndrome (A new clinical entity). Blood. 1991;77:306–310
  10. Kojouri K, Vesely S, George JN. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (Frequency, clinical features, and long-term outcomes). Ann Intern Med. 2001;135:1047–1051
  11. Moake J, Chintagumpala M, Turner N, McPherson P, Nolasco L, Steuber C, et al.  Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura. Blood. 1994;84:490–497
  12. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of von Willegrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997;89:3097–3103
  13. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, et al.  Unusually large plasma factor VIII (von Willebrand factor multimers in chronic relapsing thrombotic throbocytopenic purpura). N Engl J Med. 1982;307:1432–1435
  14. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome. Clinical experience in 108 patients. N Engl J Med. 1991;325:398–403
  15. Rock G, Sumak K, Buskard N, Blanchette VS, Kelton JG, Nair RC, et al.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991;325:393–397
  16. Shumak KH, Rock GA, Nair RC. Late relapses in individuals successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Ann Intern Med. 1995;122:569–572
  17. Byrnes JJ, Moake JL. Thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome (Evolving concepts of pathogenesis and therapy). Clin Haematol. 1986;15:413–442
  18. Bennett CL, Weinberg PD, Rozenberg-Ben Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine (A review of 60 cases). Ann Inern Med. 1998;128:541–544
  19. Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, et al.  Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000;342:1773–1777
  20. Tsai H-M, Rice L, Sarode R, Chow TW, Moake JL. Antibody inhibitors to von Willebrand factor metalloproteinase and increased von Willebrand factor-platelet binding in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med. 2000;132:794–799
  21. McMinn JR, George JN. Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregnancy. J Clin Apheresis. 2001;16:202–209
  22. Neame PD. Immunologic and other factors in thrombotic thrombocytopenic purpura (TTP). Semin Thromb Hemost. 1980;6:416–429
  23. Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA, et al.  ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (Relation to presenting features and clinical outcomes in a prospective cohort of 142 patients). Blood. 2003;102:60–68
  24. Moake JL, Byrnes JJ, Troll JH, Rudy CK, Hong SL, Weinstein MJ, et al.  Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1985;65:1232–1236
  25. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest. 1986;78:1456–1461
  26. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood. 1988;71:1366–1374
  27. Moake JL, McPherson PD. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome. Am J Med. 1989;87(suppl 3N):9N–15N
  28. Asada Y, Sumiyoshi A, Hayashi T, Suzumiji J, Kaketani K. Immunochemistry of vascular lesions in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res. 1985;38:469–479
  29. Ruggeri ZM. Developing basic and clinical research on von Willebrand factor and von Willebrand disease. Thromb Haemost. 2000;84:147–149
  30. Arya M, Anvari B, Romo GM, Cruz MA, Dong JF, McIntire LV, et al.  Ultra-large multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet GP Ib-IX complex (studies using optical tweezers). Blood. 2002;99:3971–3977
  31. Alevriadou BR, Moake JL, Turner NA, Ruggeri ZM, Folie BJ, Phillips MD, et al.  Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood. 1993;81:1263–1276
  32. Moake JL. Insolubilized von Willebrand factor and the initial events in hemostasis. J Lab Clin Med. 1989;114:1–3
  33. Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood. 1994;83:2171–2179
  34. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its confirmation and requires calcium ion. Blood. 1996;87:4235–4244
  35. Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223–4234
  36. Bork P, Beckmann G. The CUB domain-A widespread module in developmentally regulated proteins. J Mol Biol. 1993;231:530–545
  37. Tsai HM, Lian EC-Y. Antibodies of von Willebrand factor cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585–1594
  38. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al.  von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578–1584
  39. Gerritsen HE, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood. 2001;98:1654–1661
  40. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001;98:1662–1666
  41. Levy GA, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, et al.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488–494
  42. Zheng X, Chung C, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276:41059–41063
  43. Chung DW, Fujikawa K. Processing of von Willebrand factor by ADAMTS-13. Biochemistry. 2002;41:11065–11070
  44. Dong J-F, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, et al.  ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002;100:4033–4039
  45. Dong JF, Moake JL, Bernardo A, Fujikawa K, Ball C, Nolasco L, et al.  ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem. 2003;278:29633–29639
  46. Frangos JA, Moake JL, Nolasco L, Phillips MD, McIntire LV. Cryosupernatant regulates accumulation of unusually large vWF multimers from endothelial cells. Am J Physiol. 1989;256:H1635–1644
  47. Reiter RA, Knobl P, Varadi K, Turecek PL. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood. 2003;101:946–948
  48. Dong J-F, Bernardo A, Nolasco L, Padilla A, Moake J, Lopez J. ADAMTS-13 proteolysis of ultra-large von Willebrand factor multimers on the endothelial surface requires protease docking and is inhibited by thrombospondin-1. Blood. 2002;100(suppl 1):123a; (abstr 457)
  49. Bernardo A, Nolasco L, Ball C, Wang Y, Moake J, Lopez J, et al.  Peptides from the C-terminal regions of ADAMTS-13 specifically block cleavage of ultra-large von Willebrand factor multimers on the endothelial surface under flow. J Thromb Haemost. 2003; 1 July (abstr OC405) E-pub: http://www.blackwellpublishing.com/isth2003/abstract.asp (then click on Author or Subject Index)
  50. Furlan M, Robles R, Solenthaler M, Lammle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood. 1998;91:2839–2846
  51. Bianchi V, Robles R, Alberio L, Furlan M, Lammle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombotic thrombocytopenic disorders (A severely deficient activity is specific for thrombotic thrombocytopenic purpura). Blood. 2002;100:710–713
  52. Furlan M, Lammle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and the haemolytic syndrome (The role of von Willebrand factor-cleaving protease). Best Pract Res Clin Haematol. 2001;14:437–454
  53. Padilla A, Bernardo A, Nolasco L, Moake J, Lopez J, Dong J-F. A potential role for P-selectin in anchoring ultra-large von Willebrand factor multimers onto the endothelial cell surface. Blood. 2002;100(suppl 1):123a; (abstr 459)
  54. Chow TW, Turner NA, Chintagumpala M, McPherson PD, Nolasco L, Rice L, et al.  Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura. Am J Hematol. 1998;57:293–302
  55. Furlan M, Robles R, Morselli B, Sandoz P, Lammle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 1999;81:8–13
  56. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies (A study of 111 cases). Blood. 2001;98: 1765–1762
  57. Oleksowicz L, Bhagwati N, DeLoen-Fernandez M. Deficient activity of von Willebrand’s factor-cleaving protease in patients with disseminated malignancies. Cancer Res. 1999;59:2244–2250
  58. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001;98:2730–2735
  59. van der Plas RM, Schiphorst ME, Huizinga EG, Hene RJ, Verdonck LF, Sixma JJ, et al.  von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated thrombotic thrombocytopenic purpura. Blood. 1999;93:3798–3802
  60. Elliott MA, Nichols WL, Plumhoff EA, Ansell JM, Dispenzieri A, Gastineau DA, et al.  Posttransplantation thrombotic thrombocytopenic purpura (A single-center experience and a contemporary review). Mayo Clin Proc. 2003;78:421–430
  61. Tsai H-M, Chandler WL, Sarode R, Hoffman R, Jelacic S, Habeeb RL, et al.  von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli 0157 (H7-associated hemolytic uremic syndrome). Pediatr Res. 2001;49:653–659
  62. Charba D, Moake JL, Harris MA, Hester JP. Abnormalities of von Willebrand factor multimers in drug-associated thrombotic microangiopathies. Am J Hematol. 1993;42:268–277
  63. Raife TJ, Lentz SR, Atkinson BS, Vesely SK, Hessner MJ. Factor V Leiden; a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity. Blood. 2002;99:437–442
  64. Rick ME, Moll S, Taylor MA, Krizek DM, White GC, Aronson DL. Clinical use of a rapid collagen-binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 2002;88:598–604
  65. Zheng X, Nishio K, Majerus EM, Sadler JE. Cleavage of von Willebrand requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem. 2003;278:30136–30141
  66. Byrnes JJ, Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med. 1977;297:1386–1389
  67. Plaimauer B, Zimmermann K, Volkel D, Antoine G, Kerschbaumer R, Jenab P, et al.  Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood. 2002;100:3626–3632
  68. Barbot J, Costa E, Guerra M, Barreirinho MS, Isvarlal P, Robles R, et al.  Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease. Br J Haematol. 2001;113:649–651
  69. Allford SL, Harrison P, Lawrie AS, Liesner R, Mackie IJ, Machin SJ. Von Willebrand factor-cleaving protease in congenital thrombotic thrombocytopenic purpura. Br J Haematol. 2000;111:1215–1222
  70. Tsai HM. High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura. Am J Hematol. 2000;65:251–255
  71. Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis. 2002;28:385–391
  72. Chemnitz J, Draube A, Scheid C, Staib P, Schulz A, Diehl V, et al.  Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol. 2002;71:105–108
  73. Tsai HM, Shulman K. Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur J Haematol. 2003;70:183–185
  74. Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA. Remission of chronic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med. 2003;138:105–108
  75. Thompson CE, Damon LE, Ries CA, Linker CA. Thrombotic microangiopathies in the 1980s (Clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic). Blood. 1992;80:1890–1895
  76. Crowther MA, Heddle N, Hayward CPM, Warkentin T, Kelton JG. Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura. Ann Intern Med. 1996;125:294–296
  77. Kokame K, Matsumoto M, Soejima K, Yagi H, Ishizashi H, Funato M, et al.  Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA. 2002;99:11902–11907
  78. Moake JL. von Willebrand factor abnormalities in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. In:  Kaplan BS,  Trompeter RS,  Moake JL editor. Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. New York, NY: Marcel Dekker; 1992;p. 459–471

☆ Supported in part by grants from the National Institutes of Health (1P50 HL 65967) and the Mary Rodes Gibson Foundation.

PII: S0037-1963(03)00268-3

doi: 10.1053/j.seminhematol.2003.10.003

Seminars in Hematology
Volume 41, Issue 1 , Pages 4-14 , January 2004

Article Tools

* Image Usage & Resolution